New Key Statistics Module, Z-Score and F-Score
NAS:RNAC Key Ratios
| Market Cap $ M | 255.05 |
| Enterprise Value $ M | 171.30 |
| P/E(ttm) | -- |
| PE Ratio without NRI | -- |
| Forward PE Ratio | -- |
| Price/Book | -- |
| Price/Sales | 150.53 |
| Price/Free Cash Flow | -- |
| Price/Owner Earnings | -- |
| Payout Ratio % | -- |
| Revenue (TTM) $ M | 1.00 |
| EPS (TTM) $ | -5.95 |
| Beneish M-Score | -3.96 |
| 10-y EBITDA Growth Rate % | -- |
| 5-y EBITDA Growth Rate % | -- |
| y-y EBITDA Growth Rate % | -- |
| EV-to-EBIT | -3.24 |
| EV-to-EBITDA | -3.41 |
| PEG | -- |
| Shares Outstanding M | 30.26 |
| Net Margin (%) | -10,283.75 |
| Operating Margin % | -6,679.69 |
| Pre-tax Margin (%) | -10,906.16 |
| Quick Ratio | 7.48 |
| Current Ratio | 7.48 |
| ROA % (ttm) | -45.61 |
| ROE % (ttm) | -- |
| ROIC % (ttm) | -50.87 |
| Dividend Yield % | -- |
| Altman Z-Score | -4.51 |
RNAC Number of Guru Trades
RNAC Volume of Guru Trades
Gurus Latest Trades with NAS:RNAC
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
NAS:RNAC is held by these investors
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Cartesian Therapeutics Inc Insider Transactions
No Available Data
News about NAS:RNAC
Total 0- 1
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers